Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Neurizon Therapeutics Limited**
ABN	**35 094 006 023**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sergio Duchini
Date of last notice	17 May 2024

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Kelbury Pty Ltd Mr Duchini is a Director of the above holder which is the registered holder of the securities
Date of change	1 November 2024
No. of securities held prior to change	Nil
Class	Fully paid ordinary shares
Number acquired	1,315,789 fully paid ordinary shares
Number disposed	-

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.19 (19 cents) per share = $250,000
No. of securities held after change	Indirect 1,315,789 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Tranche 2 Placement as announced on 21 June 2024 and as approved by shareholders at the Company's Annual General Meeting held on 9 October 2024

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Neurizon Therapeutics Limited**
ABN	**35 094 006 023**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr. Michael Thurn
Date of last notice	29 July 2024

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	**Dr Michael Joseph Thurn & Mrs Carmen Leeann Thurn <Thurn Family A/C>** Mr Thurn is a beneficiary of the above holder which is the registered holder of the securities **Dr Michael Thurn <Thurn Family A/C>** Mr Thurn is a beneficiary of the above holder which is the registered holder of the securities
Date of change	1) 1 November 2024 2) 7 November 2024 3) 7 November 2024

+ See chapter 19 for defined terms.

No. of securities held prior to change	Indirect – Dr Michael Joseph Thurn & Mrs Carmen Leeann Thurn <Thurn Family A/C> - 2,557,895 fully paid ordinary shares - 500,000 Listed Options (NUZOA), expiring 30 April 2026 @ $0.15 Indirect – Dr Michael Thurn <Thurn Family A/C> - 1,000,000 Unlisted Options, expiring 19/01/2026 @ $0.175
Class	1) Fully paid ordinary shares 2) Performance Rights 3) Unlisted Options, expiring 30/06/2032 @ $0.20
Number acquired	Indirect 1) 263,158 fully paid ordinary shares Direct 2) 1,140,000 Performance Rights expiring 30/06/2027 3) 4,256,000 Unlisted Options, expiring 30/06/2032 @ $0.20
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1) $0.19 (19 cents) per share = $50,000 2) Nil 3) Nil

+ See chapter 19 for defined terms.

No. of securities held after change	Indirect – Dr Michael Joseph Thurn & Mrs Carmen Leeann Thurn <Thurn Family A/C> - 2,821,053 fully paid ordinary shares - 500,000 Listed Options (NUZOA), expiring 30 April 2026 @ $0.15 Indirect – Dr Michael Thurn <Thurn Family A/C> - 1,000,000 Unlisted Options, expiring 19/01/2026 @ $0.175 Direct - 1,140,000 Performance Rights expiring 30/06/2027 - 4,256,000 Unlisted Options, expiring 30/06/2032 @ $0.20
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1) Participation in the Tranche 2 Placement as announced on 21 June 2024 and as approved by shareholders at the Company's Annual General Meeting held on 9 October 2024. 2) Issue of Performance Rights as approved by shareholders at the Company's Annual General Meeting held on 9 October 2024, pursuant to Resolution 13(a). 3) Issue of Options as approved by shareholders at the Company's Annual General Meeting held on 9 October 2024, pursuant to Resolution 13(a).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Neurizon Therapeutics Limited**
ABN	**35 094 006 023**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Marcus Hughes
Date of last notice	29 July 2024

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	**Mr Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C>** Marcus Hughes is a beneficiary of the above holder which is the registered holder of the securities **Ms Antoinette Quinlan** Spouse of Marcus Hughes
Date of change	1 November 2024

+ See chapter 19 for defined terms.

No. of securities held prior to change	Direct - 9,312,500 fully paid ordinary shares Indirect - Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C> - 2,085,895 fully paid ordinary shares Indirect – Ms Antoinette Quinlan - 423,895 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	2,631,579 fully paid ordinary shares
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.19 (19 cents) per share = $500,000
No. of securities held after change	Direct - 11,944,079 fully paid ordinary shares Indirect - Marcus Paul Hughes & Mr Adam Nicholas Hughes & Mrs Joanne Elvira Hughes <Hughes Family Super Fund A/C> - 2,085,895 fully paid ordinary shares Indirect – Ms Antoinette Quinlan - 423,895 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Tranche 2 Placement as announced on 21 June 2024 and as approved by shareholders at the Company's Annual General Meeting held on 9 October 2024

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Neurizon Therapeutics Limited**
ABN	**35 094 006 023**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Kathryn MacFarlane
Date of last notice	19 June 2024

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	1 November 2024
No. of securities held prior to change	Nil
Class	Fully paid ordinary shares
Number acquired	263,158 fully paid ordinary shares
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.19 (19 cents) per share = $50,000

+ See chapter 19 for defined terms.

No. of securities held after change	263,158 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Tranche 2 Placement as announced on 21 June 2024 and as approved by shareholders at the Company's Annual General Meeting held on 9 October 2024

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.